Harbor Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Harbor Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23K	Buy	+410	New	+$21.3K	﹤0.01%	828

Other funds holding RPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

NSCM

New South Capital Management Memphis, Tennessee $2.28B AUM 47.19% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Harbor Capital Advisors's RPRX Position: Q2 2026 in Review

Harbor Capital Advisors opened a new position in Royalty Pharma (RPRX) in Q2 2026: 410 shares worth $23K. The stake represents ﹤0.01% of the portfolio and ranks #828 among its holdings.

365 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Harbor Capital Advisors held 410 shares of Royalty Pharma worth $23K as of Q2 2026.
Royalty Pharma was a new Harbor Capital Advisors position in Q2 2026.
Royalty Pharma made up ﹤0.01% of Harbor Capital Advisors's portfolio in Q2 2026, its #828 holding.
365 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Harbor Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.